Neglected Tropical Diseases (NTDs) are among the most common groups of diseases affecting over one billion people globally and are disproportionately concentrated in remote, underserved, and marginalized communities. Efforts toward NTD elimination have largely relied on preventive chemotherapy (PC), large-scale distribution of free, safe, and effective medicines to at-risk populations. One major challenge threatening elimination efforts is the poor participation of mobile and migrant populations (MMPs) in treatment programs. Despite this gap, few studies have explored strategies to improve access among these underserved populations. This study aims to determine the burden of NTDs among MMPs and explore strategies for expanding access to preventive chemotherapy through social and occupational networks using community mapping and participatory action research approaches in Nigeria. This project is a multi-site implementation research study involving 15 communities across three Nigerian states-Taraba, Akwa Ibom, and Ondo-representing pastoralist, fishing, and agrarian settings, respectively. The study comprises four phases. The first two formative phases will assess the baseline burden of NTDs and coverage of preventive chemotherapy interventions using community surveys, parasitological and serological assessments, mapping, and participatory workshops to identify migration patterns, anchor points, and social and occupational networks that could support expansion of PC. The third phase will use participatory approaches to co-construct context-specific strategies for expanding access to preventive chemotherapy among MMPs. In the fourth phase, the co-developed strategies will be implemented and evaluated for impact using established implementation research frameworks and mixed methods approaches. Through this project, investigators will develop and evaluate a novel strategy for expanding access to PC among MMPs. The study will generate evidence on the feasibility, acceptability, reach, and sustainability of the proposed approach and is expected to inform adaptable implementation models for inclusive NTD programming in Nigeria and similar endemic settings.
Age range
5 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Reach percentage measured as the proportion of eligible mobile and migrant populations (MMPs) offered preventive chemotherapy during the modified mass administration of medicines (MAM) campaign
Timeframe: Baseline ( to estimate reach in the previous MAM) and immediately after completion of the modified MAM campaign (up to 4 weeks after intervention).
Coverage percentage measured as the proportion of eligible MMPs who swallowed preventive chemotherapy during the modified MAM campaign
Timeframe: Baseline (previous MAM campaign) and immediately after completion of the modified MAM campaign (up to 4 weeks after intervention).
Compliance percentage measured as the proportion of MMPs who swallowed all medicines received during the modified MAM campaign
Timeframe: Baseline (previous MAM campaign) and immediately after completion of the modified MAM campaign (up to 4 weeks after intervention).
Acceptability rate (%) of the modified MAM strategy among mobile and migrant populations measured using a study-specific binary questionnaire informed by Proctor's Implementation Outcomes Framework
Timeframe: Immediately after completion of the modified MAM campaign (up to 4 weeks after intervention).
Prevalence of preventive chemotherapy-targeted neglected tropical diseases among mobile and migrant population children
Timeframe: Baseline (prior to implementation of the modified MAM strategy; within the fourth month of the study).
Adoption rate (%) measured as the proportion of planned anchor sites intending to implement the modified mass administration of medicines (MAM) strategy
Timeframe: Immediately following validation of the modified MAM strategy during the final participatory planning meeting (within the fourth month of the study).
Penetration rate (%) measured as the proportion of planned anchor sites implementing the modified mass administration of medicines (MAM) strategy
Timeframe: Immediately after completion of the modified MAM campaign (up to 4 weeks after intervention).
Implementation fidelity (%) measured as adherence to the planned components of the modified mass administration of medicines (MAM) strategy
Timeframe: Throughout implementation of the modified MAM campaign and immediately after campaign completion (up to 4 weeks after intervention initiation).
Appropriateness rate (%) of the modified mass administration of medicines (MAM) strategy among mobile and migrant populations and community drug distributors measured using a study-specific binary questionnaire informed by Proctor's Implementation Outcom
Timeframe: Immediately after completion of the modified MAM campaign (up to 4 weeks after intervention).
Feasibility rate (%) of the modified mass administration of medicines (MAM) strategy among mobile and migrant populations and community drug distributors measured using a a binary questionnaire informed by Proctor's Implementation Outcomes Framework
Timeframe: Immediately after completion of the modified MAM campaign (up to 4 weeks after intervention).
Sustainability rate (%) measured as the proportion of implementers able to continue the modified mass administration of medicines (MAM) strategy without additional monitoring or external support
Timeframe: Immediately after completion of the modified MAM campaign (up to 4 weeks after intervention).
Implementation cost of the modified mass administration of medicines (MAM) strategy measured using programme expenditure and resource utilization records
Timeframe: From intervention initiation through completion of the modified MAM campaign (approximately 4 weeks).